Further Product Information

ABOUT THE AUTHOR

Peter Norman is a pharmaceutical consultant and analyst with specialist knowledge of the respiratory disease and inflammation markets. He has written and presented widely on various aspects of respiratory disease and on the analysis of therapeutic markets. Dr. Norman has over 20 years experience of the pharmaceutical industry in both R&D and competitive intelligence. His publications include many reviews and management reports, sixteen original scientific papers and eleven patents. Dr. Norman holds science degrees from Cambridge University and Brunel University plus a M.B.A. degree from the Open University.

SUMMARY

"The period 2005 to 2009 will see the expiration of patent protection for 39 major drugs in the United States, an average of 8 a year. With 2004 seeing a decline in the number of NCEs approved down to 23 from 27 in 2003, there is clear evidence that the loss of revenue from patent protected drugs will impact upon the growth of the industry when so few new drugs are reaching the market."

Once patent protection and periods of marketing exclusivity expire for a branded drug, sales tend to decline dramatically as generic substitutes capture market share.

Patent expiration for a major product can see revenues for the supplier fall ten-fold within two years. The loss of patent protection for key products is increasingly significant in assessing the future performance of major pharmaceutical companies. The decline of revenues to generic substitutes has a major influence on the financial performance of such companies. Conversely, the successful identification and exploitation of the opportunities afforded by patent expirations provides a major growth driver for the pharmaceutical companies who focus their business on the provision of generic therapeutics.

With this background, Urch Publishing commissioned a study into the effect of patent expiries on some of the major branded pharmaceutical products.

Generic Competition to 2009 provides the concise and accurate overview of forthcoming generic competition.

Key features of this report.